Major Singapore provider of biotech co-working laboratory and office space, NSG BioLabs, has formed a partnership with Merck Singapore.
The life science business of Merck Singapore and NSG have formed the partnership to give biotech start-ups access to resources and expertise to bolster the research and development capabilities of NSG Biolabs' tenants.
This will thereby facilitate opportunities for funding, partnerships, production, and commercialisation.
Since its inception, NSG BioLabs has been supporting biotech startups and multinational companies by providing BSL-2 certified private and shared laboratory spaces and offices, equipment, privileged access with service providers and suppliers, and community engagement.
NSG BioLabs’ shared BSL2 wet-lab space offers a range of services and facilities essential for biotech companies, including:
- Biosafety Level 2 (BSL2) certified laboratory facility for molecular, cellular, and microbiological research
- Fully equipped BSL-2 laboratory facility with HEPA Filtered HVAC systems
- Dedicated rooms for tissue culture and microbiological work
- Amenities for laboratory and office space
This partnership will grant our residents exclusive access to Merck's scientists and engineers, state-of-the-art equipment, consumables, and services
As of 2024, NSG BioLabs has been assisting innovators in creating impactful solutions in the health, biomedical, agrifood, and industrial biotechnology sectors, working in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, synthetic biology, and other areas.
With the largest co-working biotech laboratory and office footprint in Singapore, coupled with extensive networks with local and international partners, suppliers, and industry experts, NSG BioLabs has helped over 40 companies as residents.
The company's residents include several multi-billion-dollar multinationals as well as many promising startups that have achieved key milestones. The startup residents alone have successfully raised nearly US$400m in funding and supported hundreds of jobs.
Merck Singapore's partnership with NSG Biolabs underscores our commitment to supporting the growth and development of the biotech community in Singapore and across Asia Pacific
"This partnership will grant our residents exclusive access to Merck's scientists and engineers, state-of-the-art equipment, consumables, and services, enabling them to advance their research and expand their innovations," said Daphne Teo, CEO and Founder of NSG BioLabs.
Speaking on the collaboration, Chua Keng Hock (pictured left), Managing Director of Merck Singapore, and Senior VP of Process Solutions for APAC, said: "Merck Singapore's partnership with NSG Biolabs underscores our commitment to supporting the growth and development of the biotech community in Singapore and across Asia Pacific."
"Merck offers one of the broadest portfolios in the industry for research discovery to pharmaceutical development and testing, and manufacturing of traditional and novel modalities, and access to the M Lab (trademarked) Collaboration Center in Singapore for off-site trial support and training on large equipment in a GMP-like environment," Keng Hock added.
NSG history
After its first site opening in November 2019, NSG BioLabs expanded with its second site in August 2021, and recently in 2023 with its third site.
In 2024, with three sites totalling 35,000 sqft located in the heart of Singapore's R&D ecosystem, NSG BioLabs has cemented its space as a key hub for biotech innovation.
As one of the largest private biotech incubators in the region, coupled with its strong partnerships and strategic investors, such as Celadon Partners and ClavystBio, a life sciences investor set up by Temasek, NSG BioLabs is poised to enhance its value-add offerings of infrastructure, services, and networks for its growing community.
